---
title: "BriaCell shows tumors regression in metastasized cancer patients with liver, brain involvement. Study details included."
description: "BriaCell Therapeutics Corp., a clinical-stage biotechnology company listed on both Nasdaq (BCTX, BCTXW, BCTXZ, BCTXL) and TSX (BCT), has recently shared new images showcasing the successful treatment "
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/273991857.md"
published_at: "2026-01-28T12:31:40.000Z"
---

# BriaCell shows tumors regression in metastasized cancer patients with liver, brain involvement. Study details included.

> BriaCell Therapeutics Corp., a clinical-stage biotechnology company listed on both Nasdaq (BCTX, BCTXW, BCTXZ, BCTXL) and TSX (BCT), has recently shared new images showcasing the successful treatment of metastatic breast cancer in patients with lesions in the eye, brain, liver, and spine. The company's Phase 2 study includes survival data on these patients and others, which has been previously disclosed. This development demonstrates the potential of BriaCell's immunotherapies to revolutionize cancer care.

BriaCell Therapeutics Corp., a clinical-stage biotechnology company listed on both Nasdaq (BCTX, BCTXW, BCTXZ, BCTXL) and TSX (BCT), has recently shared new images showcasing the successful treatment of metastatic breast cancer in patients with lesions in the eye, brain, liver, and spine. The company's Phase 2 study includes survival data on these patients and others, which has been previously disclosed. This development demonstrates the potential of BriaCell's immunotherapies to revolutionize cancer care.

### Related Stocks

- [BIB.US - Proshares Ultra Nasdaq Biotech](https://longbridge.com/en/quote/BIB.US.md)
- [ARKG.US - Ark Genomic Revolution ETF](https://longbridge.com/en/quote/ARKG.US.md)
- [IBB.US - iShares Biotechnology ETF](https://longbridge.com/en/quote/IBB.US.md)
- [IBBQ.US - Invesco Nasdaq Biotechnology ETF](https://longbridge.com/en/quote/IBBQ.US.md)
- [IXJ.US - iShares Global Healthcare](https://longbridge.com/en/quote/IXJ.US.md)
- [IHE.US - iShares US Pharma](https://longbridge.com/en/quote/IHE.US.md)
- [FBT.US - First Trust NYSE Arca Biotech Index Fd](https://longbridge.com/en/quote/FBT.US.md)
- [BCTXL.US - BRIACELL THERAPEUTICS CORP C/WTS 15/01/2031 (TO PUR  COM)](https://longbridge.com/en/quote/BCTXL.US.md)
- [SBIO.US - ALPS Medical Breakthrough](https://longbridge.com/en/quote/SBIO.US.md)
- [BBH.US - VanEck Biotech ETF](https://longbridge.com/en/quote/BBH.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| MoonLake Immunotherapeutics' Spine Disease Treatment Shows Improvement in a Phase 2 Study | MoonLake Immunotherapeutics announced positive results from a Phase 2 clinical trial of its drug SLK for axial spondyloa | [Link](https://longbridge.com/en/news/276582079.md) |
| EXPLAINER-Will Bayer’s proposed $7.25 billion Roundup deal bring legal closure? | Bayer's Monsanto unit has proposed a $7.25 billion settlement to resolve lawsuits claiming its Roundup weedkiller causes | [Link](https://longbridge.com/en/news/276304497.md) |
| Beam Therapeutics tops Q4 profit estimates, signs financing deal | Beam Therapeutics reported Q4 earnings that exceeded analyst expectations, with EPS at $2.33 and net income of $244.3 mi | [Link](https://longbridge.com/en/news/276730924.md) |
| Iovance Biotherapeutics: Strengthening Commercial Momentum and Expanding Amtagvi Runway Support Buy Rating | TD Cowen analyst Tyler Van Buren has maintained a Buy rating on Iovance Biotherapeutics (IOVA), citing strong commercial | [Link](https://longbridge.com/en/news/276776997.md) |
| Merck Divides Human Health Business Into Separate Oncology, Infectious Diseases Units | Merck Divides Human Health Business Into Separate Oncology, Infectious Diseases Units | [Link](https://longbridge.com/en/news/276600243.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.